Antisense - Looking Forward to Key DMD Efficacy Readout in 2024
The Phase IIb trial will primarily serve as a signal finding study to determine whether the drug has sufficient efficacy to be an effective...
330 Views
Antisense Therapeutics - Breaking the mould in DMD treatment
Antisense Therapeutics is an Australian biotechnology company developing antisense oligonucleotide (ASO) therapies for the treatment of rare...
739 Views
Taxing Times For Australia
The Government's release of Re:think, its tax discussion paper, is a welcome development, designed to kick-start the conversation with the...
6k Views